← Eichor
Study identifier: NCT07016802 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

Condition: Safety · Tolerability · Adult Growth Hormone Deficiency  ·  Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

PhasePhase 1
Planned participants64
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersYes

About this study

To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers， a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers，a single subcutaneous injection of GenSc134 is in AGHD patients.

This description comes directly from the study's public registry record.

Talk to the study team

Dongyang LIU, PHD  ·  +86 18610966092  ·  liudongyang@vip.sina.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07016802